Lacovin (Minoxidil)

Minoxidil opens potassium channels in the cells of the scalp, causing vasodilation and increased blood flow to hair follicles. This enhanced circulation supplies nutrients and oxygen, while the drug also prolongs the anagen (growth) phase of the hair cycle, leading to thicker, longer hairs.

The appropriate dose of Lacovin is determined by a qualified prescriber based on the individual’s condition, age, and response to therapy. Patients should follow the specific instructions provided on the product label or by their healthcare professional.

The safety of minoxidil in pregnancy or while breastfeeding has not been established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks with their healthcare provider before using Lacovin.

To order Lacovin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lacovin’s active ingredient, minoxidil, is the only FDA‑approved topical agent for androgenetic alopecia and is available over the counter. Compared with oral finasteride, which works hormonally, minoxidil acts locally on the scalp and does not affect systemic hormone levels, offering a different safety and mechanism profile.

Lacovin should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and extreme temperatures to maintain its stability and effectiveness.

Lacovin is applied topically to a clean, dry scalp. The recommended amount is usually a few drops or a measured amount as instructed by the prescriber, spread evenly over the affected area and gently massaged in. Hands should be washed after application.

Serious risks, though rare, include severe allergic reactions such as rash, swelling, or difficulty breathing, and cardiovascular effects like chest pain, rapid heartbeat, or dizziness. If any of these occur, discontinue use immediately and seek medical attention.

Individuals with known hypersensitivity to minoxidil or any component of the formulation should avoid Lacovin. It is also contraindicated on inflamed, infected, or broken skin, and should be used with caution in patients taking systemic antihypertensive medications.